CNBX Pharmaceuticals Inc.
CNBXOTCHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $130,074 | $410,165 | $29,958 | $0 | $7,157 |
| Operating income | −$271,691 | −$583,139 | −$931,380 | −$3.0M | −$2.6M | −$3.0M |
| Net income | −$313,976 | −$695,198 | −$3.7M | −$3.7M | −$3.2M | −$7.5M |
| Total assets | $18,437 | $31,383 | $499,039 | $811,166 | $3.1M | $2.2M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$2.5M | −$2.5M | −$2.0M | $1.6M | $1.8M | $1.8M |
| EPS (diluted) | $0.00 | $-0.02 | $-0.42 | $-3.59 | $-0.02 | — |
| Shares out. | 554.0M | 31.1M | 28.3M | 1.3M | 148.7M | 135.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 12.6%
- Return on assets
- −1703.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −773.8%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 1 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Apr 15, 2024
- NT 10-Qmissed a reporting deadline ↗Jan 14, 2019
- NT 10-Kmissed a reporting deadline ↗Nov 29, 2017
- NT 10-Kmissed a reporting deadline ↗Nov 29, 2016
- NT 10-Qmissed a reporting deadline ↗Apr 15, 2016
- NT 10-Qmissed a reporting deadline ↗Jan 14, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cannabics Inc.10% owner | Jul 25, 2014 | Sell | 18.2M | — |
| Cannabics Inc.10% owner | Jun 23, 2014 | Sell | 14.5M | $0.01 |
| Cannabics Inc.10% owner | May 8, 2014 | Sell | 20.5M | $0.01 |
| Mills Thomas E10% owner | Apr 25, 2014 | Sell | 20.5M | $0.01 |
| Mills Thomas E10% owner | Oct 28, 2013 | Buy | 20.0M | $100000.00 |
| Mills Thomas E10% owner | Jun 24, 2013 | Buy | 20.0M | $0.01 |
| North American Mining Corp10% owner | Nov 8, 2011 | J | 31.0M | $0.00 |
| Hilford Lou10% owner | Sep 25, 2007 | Sell | 2.0M | $0.00 |
| Mills Thomas EOfficer — President, CEO, CFO | Sep 25, 2007 | Buy | 2.0M | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 1.0 | +70145.1% |
| Apr 30, 2026 | 3,630 | 1.0 | -90.7% |
| Apr 15, 2026 | 38,959 | 1.0 | -2.5% |
| Mar 31, 2026 | 39,960 | 1.0 | 0.0% |
| Mar 13, 2026 | 39,960 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMar 17, 2026
- Entered a material agreementJan 30, 2025
- Changed auditorMar 22, 2024
- Director / officer changeFeb 8, 2023
- Director / officer changeDec 29, 2022
- Director / officer changeJul 25, 2022
- Amended charter or bylawsMay 13, 2022
- Amended charter or bylaws · Other material eventMar 28, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 8, 2026
- 10-QFORM 10-QApr 14, 2026
- 8-KFORM 8-KMar 17, 2026
- SCHEDULE 13G/AFeb 5, 2026
- 10-QQUARTERLY REPORTJan 14, 2026
- 10-KFORM 10-K FOR AUG 2025Dec 1, 2025
- SCHEDULE 13G/ANov 10, 2025
- SCHEDULE 13G/AAug 13, 2025
- 10-QFORM 10-QJul 14, 2025
- SCHEDULE 13G/AMay 13, 2025
- 10-QApr 14, 2025
- SCHEDULE 13G/AFeb 13, 2025
- 8-KFORM 8-KJan 30, 2025
- 10-QFORM 10-Q FOR NOV 2024Jan 13, 2025
- 10-KFORM 10-K FOR AUGUST 2024Nov 29, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.